New Swedish Manufacturing Facility of Viragen for Multiferon(TM)
Viragen confirmed that its Swedish manufacturing facility in Ersboda is on schedule to commence with the production of Multiferon(TM) in September. The Company has been upgrading and expanding its production capabilities as a result of a more aggressive business direction for its natural human alpha interferon drug. The Company previously reported that it expects to report data later this year from studies evaluating Multiferon for the treatment of malignant melanoma.
"The combined manufacturing capabilities of our existing facility in Umea with our new facility in Ersboda will provide us with the compliance and capacity necessary to focus on our goal to make Multiferon the world's most prescribed natural human alpha interferon," stated Viragen's CEO Mr. Charles A. Rice. Construction of the Ersboda facility was completed earlier this year and is currently undergoing validation required by the Swedish regulatory authorities.
Mr. Rice added, "I plan to personally observe the resumption of production activities in Sweden in September. With our current inventory of frozen Multiferon, which has a longer expiry date than finished product, we are well positioned to support our ongoing business as well as pending new activities."
Other news from the department manufacturing
